Objective Cystic fibrosis (CF), caused by mutations in the CF transmembrane conductance regulator (CFTR) gene, continues to present diagnostic challenges. Newborn screening and an evolving understanding of CF genetics have prompted a reconsideration of the diagnosis criteria.
Study design To improve diagnosis and achieve standardized definitions worldwide, the CF Foundation convened a committee of 32 experts in CF diagnosis from 9 countries to develop clear and actionable consensus guidelines on the diagnosis of CF and to clarify diagnostic criteria and terminology for other disorders associated with CFTR mutations. An a priori threshold of ≥80% affirmative votes was required for acceptance of each recommendation statement.
Results After reviewing relevant literature, the committee convened to review evidence and cases. Following the conference, consensus statements were developed by an executive subcommittee. The entire consensus committee voted and approved 27 of 28 statements, 7 of which needed revisions and a second round of voting.
Conclusions It is recommended that diagnoses associated with CFTR mutations in all individuals, from newborn to adult, be established by evaluation of CFTR function with a sweat chloride test. The latest mutation classifications annotated in the Clinical and Functional Translation of CFTR project (http://www.cftr2.org/index.php) should be used to aid in diagnosis. Newborns with a high immunoreactive trypsinogen level and inconclusive CFTR functional and genetic testing may be designated CFTR-related metabolic syndrome or CF screen positive, inconclusive diagnosis; these terms are now merged and equivalent, and CFTR-related metabolic syndrome/CF screen positive, inconclusive diagnosis may be used. C ystic fibrosis (CF) is the most common life-threatening autosomal recessive disease in the US, affecting approximately 1 in 4000 newborns in the US, [1] [2] [3] and occurring at higher frequencies in some European countries. 4, 5 CF is a multisystem disorder caused by mutations in the gene for the CF transmembrane conductance regulator (CFTR), which encodes an ion channel protein, 6 with more than 2000 mutations identified to date (http://www.genet.sickkids.on.ca/ cftr/app 7 ). A diagnosis of CF initially relied on phenotype, with clinical recognition of characteristic signs and symptoms. 8, 9 However, because of widespread CF newborn screening (NBS), at least 64% of new CF diagnoses in the US now occur in asymptomatic or minimally symptomatic infants following a positive NBS result. 10 Although the majority of infants who screen positive can be readily diagnosed with CF after a confirmatory test showing high sweat chloride concentration, the diagnosis is not clear in some individuals, 11, 12 leading to persistent challenges 13 and stresses, including a potentially disturbed parent/child relationship. [14] [15] [16] Furthermore, universal NBS was implemented only recently in the US, and many individuals born prior to 2010 have not been screened. Diagnosis of CF in the nonscreened population can be challenging because the age of onset and severity of symptoms can differ greatly as a result of highly variable levels of CFTR dysfunction. Presenting manifestations can include pancreatitis, respiratory symptoms, chronic sinusitis, and male infertility. 9, [17] [18] [19] The last few years have seen significant growth of phenotypic and genotypic information on CF that can help with interpretation of the disease status in many patients. International collection of clinical data from individuals with CF 20 and laboratory advances 21 provide insight into the functional and physiological impact of the most common mutations. 22 Because of this new information, and to seek harmony with the diagnostic criteria and terminology 23 of the European CF Society (ECFS), it was decided that the 2008 diagnostic guidelines 24 of the CF Foundation should be revised.
The CF Foundation convened an international committee of experts in the diagnosis of CF to update diagnostic guidance and achieve standardization in definitions worldwide. The mission of this committee was to develop clear and actionable consensus guidelines on diagnosis of CF and other conditions associated with mutations in the CFTR gene such as CFTR-related metabolic syndrome (CRMS) 25 or CF screen positive, inconclusive diagnosis (CFSPID), 26 and CFTR-related disorders. 27 The recommendations in this article address individuals with both clear and unclear diagnoses, including infants with positive NBS (defined as any result other than normal) and/or prenatal diagnosis, 28 and individuals with CFlike symptoms who were either never screened or who had false negative newborn or prenatal screening results. 9 Case studies, designed to show how the recommendations should be applied in challenging clinical scenarios, can be found in additional articles published throughout this Supplement.
9,28,29

Methods
An international consensus committee was selected and tasked with the development of guidelines on the diagnosis of CF; 32 experts made up this committee. Committee selection was designed to include participants representative of worldwide CF care communities, particularly pediatric CF providers with NBS experience, and other relevant specialists, including adult CF providers. Before the consensus conference, the committee reviewed the existing CF Foundation diagnosis guidelines 24 and a list of publications on CF diagnosis published since the 2008 CF Foundation Diagnosis Guidelines, including 10 key articles selected by conference cochairs. The conference was held immediately prior to the North American CF Conference in October 2015.
At the consensus conference, committee members presented and discussed new studies and data on CF diagnosis. An executive subcommittee, consisting of 10 representatives from 4 countries, developed the consensus statements at subsequent meetings. These statements were reviewed by the entire consensus committee and voted on by the members using an electronic survey tool (SurveyMonkey, Palo Alto, California). 30 An a priori threshold of ≥80% affirmative votes was required for acceptance. Individuals voting against a statement were asked to provide a revised statement and/or explanation for their vote. Feedback on the statements that did not reach 80% agreement was reviewed by the committee cochairs, and those statements were revised with input from the rest of the executive subcommittee. The revised statements were then resubmitted for voting.
After the recommendation statements were agreed upon, they were presented to the ECFS at the Diagnostic Network Working Group annual meeting in February 2016 to help engage all parties in the discussion. The draft manuscript was distributed for feedback from the executive subcommittee, conference committee, the CF Foundation's CF Center Committee, all CF centers in the US, parents of screened infants, and a variety of international organizations and their members during a public comment period.
Results
In the survey, participants were able to vote in agreement, disagreement, or to abstain. However, in each of the 2 surveys distributed for reviewing the consensus statements and voting, 1 committee member (a different person each time) did not respond. Thus, the 1 committee member who did not participate in the first voting exercise did not constitute an abstention. A vote was taken on 28 statements initially; 8 did not reach at least 80% agreement. The 8 statements that did not pass were reviewed and revised, and reduced to 7 statements by the chairs and the executive committee and sent out for a second round of voting. All but 1 member of the 32 committee members participated in this vote (ie, 1 was nonresponsive). All 7 of the revised statements passed the 80% threshold in the second round of voting.
The committee approved 27 consensus statements (Table I) in 4 overlapping categories that apply to: (1) both screened and nonscreened populations; (2) newborn screened populations and fetuses undergoing prenatal testing; (3) infants with uncertain diagnosis and designated either CRMS or CFSPID (now considered to be the same); and (4) patients presenting clinically who represent nonscreened populations, including children born at home or in regions before NBS implementation, those with false negative screening tests, and older nonscreened individuals.
The Figure provides a simplified algorithm for how these consensus statements should be applied to individuals suspected of having CF because of a positive NBS result, the appearance of signs or symptoms, or recognition of immediate family history of CF (most often sibling, but may also include Volume 181S • February 2017 In individuals with a positive newborn screen but variable or uncharacterized CFTR mutations (<2 CF-causing mutations), the diagnosis of CF can be made by demonstrating CFTR dysfunction (a sweat chloride ≥ 60 mmol/L or CF-typical NPD or ICM).
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93% 0 16
The term CRMS is used in the US for healthcare delivery purposes and CFSPID is used in other countries, but these both describe an inconclusive diagnosis following NBS. The decision to reclassify children designated as CRMS/CFSPID as CF is an integrated decision that should take into account functional assessment of CFTR (sweat chloride, and possibly NPD/ICM), CFTR genetic analysis, and clinical assessment by the CF clinicians caring for the patient.
90% 0
23
Genetic counseling should be offered to families of individuals followed for CRMS/CFSPID, including a discussion of the risk in future pregnancies.
100% 1 24
Research Recommendation: Infants with a designation of CRMS/CFSPID (by definition) do not have clinical features consistent with a diagnosis of CF and further research is needed to determine the prognosis and best practices for frequency and duration of follow-up.
96% 0 25
For individuals presenting with CF symptoms, the same diagnostic criteria recommended for the screened population for sweat chloride testing, CFTR genetic analysis, and CFTR functional testing should be used to confirm a CF diagnosis.
93% 0 26
The diagnosis of CFTR-related disorder has been defined as a monosymptomatic clinical entity (CBAVD/pancreatitis/ bronchiectasis) associated with CFTR dysfunction that does not fulfill the diagnostic criteria for CF.
86% 2 27
Clinicians should avoid the use of terms like classic/nonclassic CF, typical/atypical CF, delayed CF, because these terms have no harmonized definition and could be confusing for families or caregivers. parent or child). It should be noted that a positive NBS result does not mean the infant has CF; the probability of a CF diagnosis following a positive result varies greatly depending on the NBS method used. Even though many individuals enter this algorithm through a positive newborn screen in which CFTR genetic testing was done, the diagnosis of CF is primarily based on the direct demonstration of abnormal CFTR function by measurement of chloride concentration in the sweat. 24 Although obtaining an adequate sweat specimen for chloride measurements can be challenging, particularly in very young infants, experience and studies have shown that this is feasible in full-term infants during the first postnatal month (ie, during the neonatal period). [31] [32] [33] [34] Following the committee's recommendations will improve reliability of the sweat test result. 33 The committee recognizes that many NBS programs do not report results by this time and, therefore, recommends that sweat chloride testing proceed as soon as possible after results are available; generally, this is no later than 10 days of age. Although gestational age and weight must be considered, 38 testing should occur if at all possible before the end of the neonatal period because malnutrition and other risks such as potentially fatal hyponatremic dehydration may occur even in the first few weeks of life.
Sweat Chloride Testing and Presumptive Diagnosis
39-42
Figure. CF is diagnosed when an individual has both a clinical presentation of the disease and evidence of CFTR dysfunction. The tests of CFTR function are not always done in this order, but hierarchically to establish the diagnosis of CF, sweat chloride should be considered first, then CFTR genetic analysis, and then CFTR physiologic tests. All individuals diagnosed with CF should have a sweat test and a CFTR genetic analysis performed. Rare individuals with a sweat chloride <30 mmol/L may be considered to have CF if alternatives are excluded and the other confirmatory tests (genetic, physiologic testing) support CF. If only 1 CFTR variant is identified on limited analysis, further ("extended") CFTR testing should be performed. 22 CF is possible if both alleles possess CF-causing, undefined, or mutation of varying clinical consequence (MVCC) mutations; CF is unlikely if only non-CF-causing mutations are found. If a CF diagnosis is not resolved, CRMS/CFSPID (following NBS) or CFTRrelated disorder should be considered. 9, 29 Rarely, no distinct label may be appropriate but further follow-up may be warranted. In these cases, the use of "CF carrier" or the specific clinical problem should be used for characterization/labeling purposes. 22 Some CFTR mutations, such as c.3717 + 12191C>T (legacy: 3849 + 10 kb C-> T), are associated with low sweat chloride values; in these cases, an alternative diagnosis does not need to be ruled out. Evidence may be provided by CFTR genotype 20 (an article in this Supplement provides a discussion of CFTR genetic testing and interpretation in detail 22 ) or by further CFTR physiologic testing. [64] [65] [66] [67] Other articles in this Supplement present a discussion of the demonstration of CFTR dysfunction including the use of nasal potential difference (NPD) or intestinal current measurement (ICM) on the screen-positive newborn 28 and information on the symptomatic patient. 
as a result of that allele).
The CFTR2 project provides a detailed characterization of CFTR mutations by collecting clinical and laboratory evidence of phenotypic consequence. 20 For each mutation, the CFTR2 website provides information and classification as listed above. The CFTR2 project is updated as mutation-specific functional analyses are completed. Also, because mutation categorization may change over time, it is important to confirm genotype interpretation on the most current version of the website. Mutations that are not analyzed as part of CFTR2 may still be interpretable if adequate research exists. For example, if a mutation is detected that is not annotated in CFTR2 and has been shown to be seen previously in patients with CF, has functional evidence that the nucleotide/protein change is deleterious; and does not occur commonly in databases of general (healthy) population, that mutation can be characterized as CF-causing.
(12) All populations: In individuals presenting with a positive newborn screen, symptoms of CF, or a positive family history, the identification of 2 CF-causing mutations (defined by CFTR2) is consistent with a diagnosis of CF. Sweat chloride testing is necessary, though, to confirm the diagnosis.
A sweat chloride test result ≥30 mmol/L is confirmatory in individuals with 2 CF-causing mutations on separate chromosomes. As stated above, there are situations in which repeated sweat chloride testing does not provide further clarity, such as in individuals with CFTR mutations known to be associated with normal or intermediate sweat chloride. 59, 60 Another article in this Supplement provides further exploration of this topic. 24 This is also important for families of newborns designated CRMS/CFSPID. Our understanding of the impact of various CFTR mutations is evolving and will continue to be clarified for many years. Genetic counseling is important for parents to understand the risk of a child having CF or being designated as CRMS/CFSPID in future pregnancies.
25,26 (24) For newborns (research recommendations): Infants with a designation of CRMS/CFSPID (by definition) do not have clinical features consistent with a diagnosis of CF and further research is needed to determine the prognosis and best practices for frequency and duration of follow-up.
There is inadequate evidence to recommend a standard period and frequency for follow-up of these individuals. Further research on this will require common definitions, and the merging of CRMS and CFSPID designations is, therefore, especially timely. 28, 50 who should then be considered as in the nonscreened population.) In these individuals, the diagnostic algorithm (Figure) remains applicable. However, the assignment of a diagnosis of CF will be weighed against alternative diagnostic explanations of the presenting symptom or feature. Therefore, the pretest probability of CF will influence the interpretation of sweat chloride testing, CFTR genetic analysis, or CFTR physiologic testing. Definitive diagnostic criteria for nonscreened populations include the presence of CF symptoms or a family history and sweat chloride ≥60 mmol/L OR presence of 2 CF-causing CFTR mutations and sweat chloride ≥30 mmol/L or physiologic testing demonstrating CFTR dysfunction. The diagnosis of CF also can be appropriate if the above testing is not definitive, but CFTR dysfunction is the best explanation of the patient's symptoms. In keeping with the reasons for recommending genetic analysis of newborns diagnosed with CF (statement 7) or CRMS/ CFSPID (statement 23), we suggest that all nonscreened individuals diagnosed with CF or a CFTR-related disorder also undergo genetic analysis, and they or their families be provided with genetic counseling to clarify the risk of disease in future pregnancies. Of course, as with all other diseases, it should be said that phenotype can vary in individuals with the same genotype.
General Note for the Nonscreened Individual
For the Nonscreened Individual with an Inconclusive Diagnosis
There are scenarios in which a given patient may not meet the above diagnostic criteria to be diagnosed with CF but also cannot be "ruled-out" as not having CF. Although this situation is similar to infants with CRMS/CFSPID, those classifications are not appropriate for the nonscreened populations.
(26) The diagnosis of CFTR-related disorder has been defined as a monosymptomatic clinical entity (congenital bilateral absence of the vas deferens/pancreatitis/bronchiectasis) associated with CFTR dysfunction that does not fulfill the diagnostic criteria for CF.
Individuals with a CFTRrelated disorder 27 (generally mono-organ) should be assessed and followed by a CF physician to ensure that if any additional symptoms develop that are typical of CF, they are detected. these terms have no harmonized definition and could be confusing for families or caregivers. In these and other situations, education on clinical entities and organ pathologies associated with CF and their relationship with CFTRrelated disorder should be provided to patients, families, and primary care providers to aid in the early recognition of symptoms of CF. The CF Foundation reaffirms the view that it is essential to avoid confusion of parents and patients, and also caregivers, with imprecise terms like atypical or nonclassic because early diagnosis and more effective treatments can lead to relatively mild disease for many years even in c.1521_1523delCTT (legacy: F508del) homozygotes. However, it is understood that some European countries will continue to use such terminology as they pursue research on mild cases.
ICD-10 Codes for Individuals with CFTR Dysfunction
The ICD 81 system is a medical classification list created collaboratively by the World Health Organization to be "the international standard for defining and reporting diseases and health conditions. It allows the world to compare and share health information using a common language." 82 It is an alphanumeric system containing codes for diseases, signs and symptoms, abnormal findings, complaints, social circumstances, and external causes of injury or diseases. The ICD system is valuable, indeed essential, for many purposes including: (1) entry and continuation into the healthcare delivery mechanisms of some countries such as the US where the ICD codes are an integral and required component of billing; (2) coding death certificates internationally, thus, allowing assessment of mortality data; (3) epidemiologic research; and (4) medical economics research. DIOS, distal intestinal obstruction syndrome. *Describes positive newborn screen result with an inclusive diagnosis but only applies to the newborn period and thus cannot be used in follow-up care. †Preferred over N46.025 (azoospermia because of a systemic disease).
The most recent revision of the system, ICD-10, implemented in October 2015, provides more than 14 400 different codes and can be expanded to over 16 000 codes by using optional subclassifications. It is not possible to convert ICD Ninth Revision datasets to ICD-10. In the ICD-10 coding system, characters 1-3 indicate the category of disease; 4-6 indicate etiology, anatomic site, severity or other clinical detail of disease; and character 7 is a placeholder for extending the code to increase specificity. The designation "E" indicates endocrine, nutritional, and metabolic diseases, and "J" applies to diseases of the respiratory system. Some CF specialists were engaged in the ICD-10 development process, but the degree of influence was limited, and coding for diseases or disorders caused by CFTR dysfunction is not ideal, including the absence of a code for CFTRrelated disorder. The current ICD-10 code is undergoing revision to ICD 11th Revision which is due to be completed in 2018. Participation is invited (http://www.who.int/classifications/ icd/revision/en/), and we encourage involvement by CF caregivers.
A list of ICD-10 codes that should be used in the delivery of care for those disorders associated with CFTR mutations (that is, CF, CRMS/CFSPID, and CFTR-related disorder) is shown in Table II .
Summary of Revisions to the 2008 CF Foundation Guidelines
The basic strategy necessary for diagnosis of CF in the large majority of individuals remains unchanged from the process recommended in 2008. 24 However, some of the diagnostic tools presented in this document and the recommended application of those tools in more complex clinical scenarios do represent significant changes. A summary of the main changes to the 2008 diagnostic algorithm is presented in Table III .
Discussion
Although NBS is now widely implemented, the diagnosis of CF is not always clear. A sweat test is required for confirmation of CF; a sweat chloride level ≥60 mmol/L indicates a diagnosis of CF and a sweat chloride level <30 mmol/L indicates Table III • CFTR-related disorder: a symptomatic entity that does not meet diagnostic criteria for CF
• CFTR-related disorder: Individuals with 0-1 CF-causing mutations and clinical signs (possibly multiple-organ) suggestive of CF • Avoid terms like "atypical" or "nonclassical" CF because there is no consensus definition of these terms
• Recommendation unchanged but greater emphasis now given to the importance of avoiding these imprecise, potentially confusing terms in the US. 
